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The first examples of 2,2’-bipyrimidine ligands incorporating bulky or chiral substituents 
have been prepared by nickel(0)-mediated homo-coupling reactions of chloropyrimidines. 
The 4,4’-di-(tert-butyl) derivative 2 and the chiral derivative 5, with 4,5-fused bornane 
groups, have been shown to form mononuclear metal complexes in which they coordinate 
through the less hindered nitrogen donors. 
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Heterocyclic ligands that bridge two metal centres have found numerous applications in 
coordination, organometallic and metallosupramolecular chemistry.[1-3] Ligands incorporating 
two 2,2’-bipyridine-like, chelating binding domains have been particularly important.[2] Of 
such ligands, 2,2’-bipyrimidine 1 (Figure 1) occupies a special place, as it positions the metals 
in close proximity (ca. 5.5 Å separation), thereby facilitating strong metal-metal 
interactions.[4] This ligand was first prepared over forty years ago by Ullmann coupling of 2-
bromopyrimidine, albeit in low yield.[5] Recently, two much improved syntheses of 1 were 
reported[6] that are likely to make it an even more popular bridging ligand. Surprisingly few 
substituted derivatives of 1 have been prepared and used as ligands.[4] 4,4’-Disubstituted 
derivatives are potentially capable of displaying various metal binding modes; three 
mononuclear isomers (A-C) and two binuclear isomers (D,E) can be envisaged (Figure 1). To 
our knowledge, the only such ligand previously described is the 4,4’-dimethyl compound, 
which was the subject of a cursory study of its complexes with ruthenium(II).[7] We now 
describe the syntheses and some metal complexes of two new derivatives, one of which 
contains bulky tert-butyl substituents and the other possesses fused bornane groups and 
represents the first homochiral derivative. 
[Figure 1 here] 
The 4,4’-di-(tert-butyl) derivative 2 was prepared, as shown in Scheme 1, by Ni(0)-
mediated homo-coupling of 2-chloro-4-(tert-butyl)pyrimidine. Initial attempts to effect this 
reaction using a procedure based on that of Nasielski et al.,[8] which we have found to be 
effective for related heteroaryl halides,[9] proved singularly unsuccessful. Coupling was 
finally achieved using the zinc-mediated procedure pioneered by Iyoda et al.,[10] if only in 
disappointingly low yield. This new ligand was characterized by mass spectrometry and 1H 
and 13C NMR spectroscopy. Reaction of 2 with one or two equivalents of Mo(CO)4(η4-
norbornadiene) gave an unstable red complex, which was identified by 1H NMR as the 
symmetrical mononuclear complex 3.  
[Scheme 1 here] 
Reaction of 2 with Ru(dmb)2Cl2 (dmb = 4,4’-dimethyl-2,2’-bipyridine) gave, in good 
yield, a red complex 4, which was isolated as a hexafluorophosphate salt.  This complex was 
shown by mass spectrometry to be mononuclear and its 1H and 13C NMR spectra were readily 
assigned by comparison with the spectra of related complexes.[11] In particular, the 
symmetrical nature of the complex and the high-field position of the H6,6' proton signal 
clearly identified the structure as being that of 4. The visible absorption spectrum of 4 in 
aectonitrile consists of a combination of a higher energy d−π*(dmb) MLCT transition (442 
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nm) and a lower energy d−π*(2) MLCT shoulder (480 nm). Cyclic voltammetry, in 
acetonitrile with 0.1 M Bu4NPF6 supporting electrolyte, displayed a reversible one-electron 
oxidation (E1/2 = +1.17 V, versus SCE) of the ruthenium centre, a reversible first reduction 
attributed to electron transfer into the coordinated ligand 2 (E1/2 = -1.23 V), two successive 
reversible dmb-based reductions (E1/2 = -1.68 and -1.90 V) and an irreversible further 
reduction of the coordinated ligand 2 (E1/2 = -2.11 V). This behaviour is similar to that of 
related complexes of 1,[4a,12] but with potentials shifted due to the electron donating nature of 
the tert-butyl substituents.[13] In both these complexes the ligand 2 coordinates in mode A 
(Figure 1), employing the less sterically hindered nitrogen donors, distal from the bulky tert-
butyl groups. All attempts to enforce coordination to two metal centres proved unsuccessful.  
We have previously described the syntheses of many chiral ligands comprised of bornane 
units fused to heterocyclic rings, such as pyrazole[14,15] and pyrazine.[16] As an extension of 
this work we have now synthesized the first chiral 2,2’-bipyrimidine 5, as shown in Scheme 2. 
3-Formylcamphor 6 was condensed with guanidine carbonate to give the known 
aminopyrimidine 7, which was then diazotised in conc. HCl to give a mixture of the 
pyrimidinone 8 and the chloro derivative 9, which were separated by chromatography on 
silica gel. Additional 9 was obtained from 8 by reaction in refluxing POCl3, as has been 
previously described.[17] The chloropyrimidine 9 was then subjected to nickel-mediated 
coupling to give 5 in moderate yield. This new ligand was characterised by mass spectrometry 
and 1H and 13C NMR spectra, which were assigned by comparison with the spectra of related 
chiral ligands containing a fused-bornane group.[14-16,18]  
[Scheme 2 here] 
Reaction of 5 with one equivalent of PdCl2 gave a yellow complex, which was 
characterised by elemental analysis as 10 (Scheme 2).  Although the complex was found to be 
insoluble in common NMR solvents, its structure is most likely 10 given the large size of the 
camphor substituents.  The proposed structure 10 is supported by that of the mono-
molybdenum(0) complex 11, which was prepared from reaction of 5 with either one or two 
equivalents of Mo(CO)4(η4-C7H8).  The 1H NMR spectrum of 11 clearly indicated the 
symmetrical mononuclear structure shown.  
The ruthenium(II) complex 12 (Scheme 2) was prepared by reaction of 5 with one 
equivalent of Ru(dmb)2Cl2 and isolated as a red hexafluorophosphate salt.  Analysis by mass 
spectrometry confirmed that this complex was mononuclear, whilst the symmetrical N1-N1' 
coordination shown was confirmed by the 1H and 13C NMR spectra, which were 
straightforwardly assigned by comparison with the spectra of related ligands and 
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complexes.[15] In contrast to the complex 4, in which the Δ and Λ forms of the complex are 
enantiomeric, the chiral nature of 5 means that the Δ and Λ forms of 12 are 
diastereoisomeric[19] and therefore distinguished in the 1H NMR spectrum. For example, the 
H4 protons of the pyrimidine rings of the two diastereoisomers are observed as two singlets at 
7.65 and 7.68 ppm.  Only the two most upfield singlets could be unambiguously assigned to 
specific Δ and Λ forms.  Inspection of molecular models showed that in the Δ-diastereoisomer 
the syn-9-CH3 protons (0.36 ppm) are positioned above a pyridine ring of a nearby dmb 
ligand and therefore more shielded relative to the Λ-isomer where the corresponding protons 
(0.77 ppm) are coplanar with a pyridine ring.  The complete assignment of the 1H NMR 
spectrum of the mixture of diastereoisomers of 12 would require physical separation of the Δ 
and Λ forms,[20] which was not attempted.  
The complex 12 in acetonitrile exhibits a broad visible absorption band centred around 
456 nm, which is probably a combination of MLCT transitions into the ligand 5 and the dmb 
ligands. The cyclic voltammogram of 12 in acetonitrile comprises a reversible one-electron 
oxidation (E1/2 = +1.12 V, versus SCE) and three reversible one-electron reductions (E1/2 = -
1.39, -1.69 and -1.92 V).  Thus, this complex is slightly easier to oxidise than 4, but harder to 
reduce, which reflects the increased electron donating alkyl substitution within the pyrimidine 
ring. 
In conclusion, we have prepared the first examples of 2,2-bipyrimidines with bulky or 
chiral substituents and shown that they coordinate through mode A (Figure 1), with 
coordination through the less hindered N-donors. Thus far, all attempts to enforce bridging 
coordination to two metal centres have proved fruitless. 
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Experimental 
General 
For general procedures and instrumentation see ref. 21. 2-Chloro-4-(tert-butyl)pyrimidine,[22] 
3-formylcamphor 6,[23] 2-amino-(5S,8R)-5,6,7,8-tetrahydro-8,9,9-trimethyl-5,8-
methanoquinazoline 7,[24] Ni(PPh3)2Cl2,[25] Mo(CO)4(η4-norbornadiene)[26] and 
[Ru(dmb)2Cl2][27] were prepared by literature procedures. Other reagents were obtained from 
commercial sources.  
4,4'-Di(tert-butyl)-2,2'-bipyrimidine 2 
A blue solution of Ni(PPh3)2Cl2 (750 mg, 1.15 mmol) and PPh3 (601 mg, 2.30 mmol) in 
dry dimethylformamide (20 mL) was treated with zinc dust (77 mg, 1.18 mmol) and stirred 
for 1 hour under a nitrogen atmosphere to generate a red solution.  2-Chloro-4(tert-
butyl)pyrimidine (196 mg, 1.15 mmol) was added and the mixture stirred for 40 hours.  The 
resulting mixture was poured into water (35 mL), boiled for 5 minutes and filtered.  The 
filtrate was treated with ammonium hexafluorophosphate and the resultant white precipitate 
filtered off and dissolved in 2:1 acetonitrile/water (15 mL).  Potassium cyanide (177 mg) 
(CAUTION!) was added to the solution which was then refluxed briefly, cooled and extracted 
with chloroform (3 x 15 mL).  The extracts were combined and the chloroform removed in 
vacuo.  The residue was dissolved in concentrated hydrochloric acid (5 mL), extracted with 
chloroform (3 x 5 mL) to remove triphenylphosphine, then made alkaline with aqueous NaOH 
(2 M) and re-extracted with chloroform (3 x 10 mL).  The final extracts were combined, 
whereupon evaporation of the solvent furnished the product as an off-white solid, which was 
recrystallized from ethanol/ether to give 2 (30 mg, 9.6%), mp 114-115°C.  Mass spectrum: 
M+. calcd for C16H22N4: 270.1844.  Found: 270.1840. δH (CDCl3) 1.48 (18H, s, CH3), 7.45 
(2H, d, H5), 8.91 (2H, d, H6).  δC (CDCl3) 29.8 (6C, CH3), 38.6 (2C, C(CH3)3), 117.0 (2C, 
C5), 156.1 (2C, C6), 163.1 (2C, C2), 179.2 (2C, C4). 
[4,4'- Di(tert-butyl)-2,2'-bipyrimidine]-tetracarbonyl-molybdenum 3 
A green solution of Mo(CO)4(C7H8) (16.4 mg, 0.037 mmol or 32.8 mg, 0.074 mmol) in 
THF (2 mL) was added dropwise to a stirred solution of 2 (10 mg, 0.037 mmol) in THF (5 
mL).  The resultant deep red solution was stirred for 2 hours and a layer of petroleum ether 
was added.  The solution was left to cool (0°C) overnight to give 3 as a red microcrystalline 
solid (15 mg, 85%). δH (CDCl3) 1.48 (18H, s, CH3), 7.45 (2H, d, H5), 9.08 (2H, d, H6).   
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Bis-(4,4'-dimethyl-2,2'-bipyridine)-[4,4'-di(tert-butyl)-2,2'-bipyrimidine]-ruthenium(II)-bis-
(hexafluorophosphate) 4 
4,4'-Di(tert-butyl)-2,2'-bipyrimidine 2 (18 mg, 0.067 mmol) was reacted with 
Ru(dmb)2Cl2.2H2O (34 mg, 0.059 mmol) in refluxing ethanol/water (3:1) for 5 hours. The 
mixture was cooled to room temperature, filtered to remove unreacted ligand and 
concentrated to dryness in vacuo. The resulting solid was dissolved in the minimum volume 
of water and the product precipitated by the addition of an aqueous solution of NH4PF6.  It 
was recrystallized from acetonitrile/ether to give 4 as a red microcrystalline solid (36 mg, 
52%).  FAB mass spectrum: calcd for [C40H46N8PF6Ru]+: 885.2531.  Found: 885.2535.  δH 
(CD3CN) 1.48 (18H, s, CH3), 2.59 (6H, s, dmb-CH3), 2.60 (6H, s, dmb-CH3), 7.29 (2H, d, 
dmb-H5), 7.34 (2H, d, dmb-H5). 7.56 (2H, d, dmb-H6), 7.57 (2H, d, H5), 7.74 (2H, d, dmb-
H6), 7.91 (2H, d, H6), 8.40 (4H, s, dmb-H3). δC (CD3CN) 20.6 (4C, dmb-CH3), 28.8 (6C, 
CH3), 38.5 (2C, C(CH3)3), 120.6 (2C, C5), 125.2 (4C, dmb-C3), 128.6 (2C, dmb-C5), 128.8 
(2C, dmb-C5), 150.8 (2C, dmb-C4), 150.9 (2C, dmb-C4), 151.1 (2C, dmb-C6), 151.6 (2C, 
dmb-C6), 156.8 (2C, dmb-C2), 157.0 (2C, dmb-C2), 158.7 (2C, C6), 162.7 (2C, C2), 179.6 
(2C, C4). 
2-Chloro-(5S,8R)-5,6,7,8-tetrahydro-8,9,9-trimethyl-5,8-methanoquinazoline 8 
The amine 7 (1.05 g, 5.17 mmol) was added to concentrated hydrochloric acid (5 mL) 
cooled below 0°C. Whilst maintaining the temperature below -10°C, an aqueous solution (2 
mL) of sodium nitrite (0.46 g, 6.67 mmol) was added dropwise, and the resultant mixture left 
to stir at -10°C for 1.5 hours.  The mixture was then neutralised with NaOH, allowed to warm 
to room temperature and extracted with chloroform (3 x 10 mL).  The combined extracts were 
concentrated (1-2 mL) in vacuo and absorbed onto a silica gel radial chromatography plate, 
which was eluted with chloroform to give two bands.  The first band was collected, and the 
solvent removed in vacuo, to give 8 as a clear oil, which crystallized on standing (0.55 g, 
48%), mp 84-86°C.  Mass spectrum: M+. calcd for C12H15N2Cl: 222.0924.  Found: 222.0924.  
δH (CDCl3) 0.60 (3H, s, syn-9-CH3), 1.03 (3H, s, anti-9-CH3), 1.17 (1H, m, endo-H6), 1.25 
(1H, m, endo-H7), 1.30 (3H, s, 8-CH3), 1.96 (1H, m, exo-H7), 2.19 (1H, m, exo-H6), 2.95 
(1H, d, H5), 8.22 (1H, s, H4).  The second band was collected and the solvent removed in 
vacuo to give 2-hydroxy-(5S,8R)-5,6,7,8-tetrahydro-8,9,9-trimethyl-5,8-methanoquinazoline 
9 (0.32 g, 30%), mp 213-215°C.  Mass spectrum: M+. calcd for C12H16N2O: 204.1263.  
Found: 204.1261.  δH (CDCl3) 0.70 (3H, s, syn-9-CH3), 1.01 (3H, s, anti-9-CH3), 1.16 (1H, 
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m, endo-H6), 1.38 (1H, m, endo-H7), 1.24 (3H, s, 8-CH3), 1.90 (1H, m, exo-H7), 2.12 (1H, 
m, exo-H6), 2.78 (1H, d, H5), 7.44 (1H, s, H4).  Compound 9 (0.30 g, 1.47 mmol) was 
refluxed in POCl3 to give additional 8 (185 mg, 57%).  
2,2'-Bi-(5S,8R)-5,6,7,8-tetrahydro-8,9,9-trimethyl-5,8-methanoquinazoline 5 
 A mixture of nickel chloride (0.32 g, 2.47 mmol), PPh3 (1.41 g, 5.38 mmol) and zinc 
dust (0.13 g, 2.0 mmol), in dry dimethylformamide (10 mL), was stirred at 50°C under an 
argon atmosphere. After 1 hour, during which time the colour of the mixture changed from 
blue to green and finally to red (Ni0(PPh3)2), a solution of 8 (0.3 g, 1.35 mmol), in 
dimethylformamide (3 mL), was added under an argon atmosphere, and the mixture left to stir 
at 50°C for a further 12 hours. The resultant brown mixture was poured into aqueous 
ammonia (50 ml, 2 M), filtered to remove the precipitate of triphenylphosphine oxide and the 
filtrate extracted with chloroform (3 x 40 mL). The extracts were combined and the solvent 
removed in vacuo. The residue was redissolved in chloroform (1-2 mL) and absorbed onto a 
silica gel radial chromatography plate. Excess triphenylphosphine was eluted with petroleum 
ether/ethyl acetate (1:1). Compound 5 was eluted with chloroform and the solvent removed in 
vacuo to give a white solid (0.11 g, 44%), mp 186-188°C. Mass spectrum: M+. calcd for 
C24H30N4: 374.2471. Found: 374.2471. δH (CDCl3) 0.63 (6H, s, syn-9-CH3), 1.05 (6H, s, 
anti-9-CH3), 1.25 (2H, m, endo-H6), 1.29 (2H, m, endo-H7), 1.47 (6H, s, 8-CH3), 1.95 (2H, 
m, exo-H7), 2.23 (2H, m, exo-H6), 3.02 (2H, d, H5), 8.64 (2H, s, H4). δH (CD3CN) 0.66 (6H, 
s, syn-9-CH3), 1.11 (6H, s, anti-9-CH3), 1.18 (2H, m, endo-H6), 1.35 (2H, m, endo-H7), 1.37 
(6H, s, 8-CH3), 2.03 (2H, m, exo-H7), 2.28 (2H, m, exo-H6), 3.11 (2H, d, H5), 8.58 (2H, s, 
H4). δC (CD3CN) 9.7 (2C, 8-CH3), 18.5 (2C, anti-9-CH3), 19.5 (2C, syn-9-CH3), 25.61 (2C, 
C6), 31.4 (2C, C7), 49.6 (2C, C5), 54.9 (2C, C9), 57.5 (2C, C8), 138.4 (2C, C4a), 147.4 (2C, 
C4), 162.0 (2C, C2), 179.6 (2C, C8a). 
Dichloro-[2,2'-bi-(5S,8R)-5,6,7,8-tetrahydro-8,9,9-trimethyl-5,8-methanoquinazoline]-
palladium(II) 10 
 A hot solution of PdCl2 (5 mg) in HCl (3 mL) was added dropwise to a hot solution of 
5 (11 mg, 0.06 mmol) in methanol (8 mL). The resultant pale yellow precipitate of 10 was 
filtered off and air dried (9 mg, 26%). Calcd for C24H30N4Cl2Pd.1.5H2O C: 49.80, H: 5.74, 
N: 9.68.  Found C: 50.21, H: 5.46, N: 9.76.  
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[2,2'-Bi-(5S,8R)-5,6,7,8-tetrahydro-8,9,9-trimethyl-5,8-methanoquinazoline-N3,N3']-
tetracarbonyl-molybdenum 11 
  A solution of Mo(CO)4(C7H8) (12 mg, 0.04 mmol) in dry THF (4 mL) was added 
dropwise, with stirring, to a solution of 5 (20 mg, 0.05 mmol) in dry THF (10 mL). The 
solution rapidly became deep red and was stirred for 1 hour then diluted with petroleum ether 
(6 mL) and cooled (0°C) overnight. The resultant red precipitate of 11 was filtered off and 
dried (10 mg, 43%). Similarly, a two-fold excess of Mo(CO)4(C7H8) (24 mg, 0.08 mmol) 
gave 11 (13 mg, 56%). δH (CDCl3) 0.65 (6H, s, syn-9-CH3), 1.09 (6H, s, anti-9-CH3), 1.27 
(2H, m, endo-H6), 1.42 (2H, m, endo-H7), 1.47 (6H, s, 8-CH3), 2.04 (2H, m, exo-H7), 2.30 
(2H, m, exo-H6), 3.07 (2H, d, H5), 8.81 (2H, s, H4). 
Bis-(4,4'-dimethyl-2,2'-bipyridine)-[2,2'-bi-(5S,8R)-5,6,7,8-tetrahydro-8,9,9-trimethyl-5,8-
methanoquinazoline-N3,N3']-ruthenium(II)-bis-(hexafluorophosphate) 12 
Ligand 5 (27.9 mg, 0.074 mmol) was reacted with Ru(dmb)2Cl2.2H2O (39 mg, 0.068 
mmol) as described above and the resultant solid recrystallized from acetonitrile/ether to give 
orange crystals of 12 (75mg, 91%). Calcd for C52H60N10P2F12Ru.2CH3CN C: 51.36, H: 
4.97, N: 11.52. Found C: 51.04, H: 5.06, N: 11.34. FAB mass spectrum: calcd for 
[C48H54N8PF6Ru]+: 989.316. Found: 989.317. 1H NMR showed the complex to exist as two 
diastereoisomers. δH (CD3CN) 0.36 (6H, s, Δ-syn-9-CH3), 0.77 (6H, s, Λ-syn-9-CH3), 0.96 
(2H), 1.07 and 1.12 (2 x 6H, s, anti-9-CH3), 1.22 (2H), 1.34 (2H), 1.41 and 1.45 (2 x 6H, s, 8-
CH3), 1.50 (2H), 2.12-2.31 (8H), 2.58 (24H, dmb-CH3), 2.98 and 3.02 (2 x 2H, d, H5), 7.27 
(8H, d, dmb-H5), 7.51 (2H, d, dmb-H6), 7.54 (4H, d, dmb-H6), 7.65 and 7.68 (2 x 2H, s, H4), 
7.70 (2H, d, dmb-H6), 8.39 (8H, s, dmb-H3). δC (CD3CN) δ: 9.4 and 9.5 (8-CH3), 18.2 and 
18.3 (anti-9-CH3), 19.1 and 19.8 (syn-9-CH3), 20.6 (4C, dmb-CH3), 24.8 and 24.9 (C6), 31.0 
and 31.1 (C7), 49.7 and 49.8 (C5), 55.5 (2C, C9), 58.1 and 58.2 (C8), 125.16 (2C), 125.23 and 
125.3 (2C, dmb-C3), 128.5 (2C), 128.6 and 128.7 (dmb-C5), 141.8 (2C, C4a), 148.7 and 
149.0 (C4), 150.5, 150.6 (2C) and 150.64 (dmb-C4), 151.0, 151.1, 151.4 and 151.7 (dmb-C6), 
156.85, 156.92 and 157.0 (2C, dmb-C2), 162.1 (2C, C2), 180.5 and 180.6 (C8a). 
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Fig. 1. Structure 2,2'-bipyrimidine and possible coordination modes for mononuclear (A-C) 
and homobinuclear (D,E) complexes of 4,4'-disubstituted derivatives. 
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